Ali Asif's Form 4 filing
Protagonist Therapeutics, IncPTGX · filed Jan 27, 2026
- Accession no.
- 0001104659-26-007128
- Filed
- Jan 27, 2026
- Trade date
- Jan 27, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.84M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ali AsifCIK 0001921163 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Common Stock | MOption exerciseAcquired | +16,000 | $19.19 | +$307,040 | 94,523 | Direct | |
| Jan 27, 2026 | Common Stock | MOption exerciseAcquired | +12,000 | $12.17 | +$146,040 | 106,523 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −28,000 | $83.13F2 | −$2,327,640 | 78,523 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −18,203 | $83.14F3 | −$1,513,397.42 | 60,320 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Common Stock | MOption exerciseDisposed | −16,000 | $0.00 | $0 | 50,800 | Direct | |
| Jan 27, 2026 | Common Stock | MOption exerciseDisposed | −12,000 | $0.00 | $0 | 18,547 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.